MDP vs. FIRE, EPI, CPH, ICC, OGI, RIV, LEAF, CRDL, RX, and HLS
Should you be buying Medexus Pharmaceuticals stock or one of its competitors? The main competitors of Medexus Pharmaceuticals include Supreme Cannabis (FIRE), ESSA Pharma (EPI), Cipher Pharmaceuticals (CPH), ICC Labs (ICC), Organigram (OGI), RIV Capital (RIV), Leaf Mobile (LEAF), Cardiol Therapeutics (CRDL), BioSyent (RX), and HLS Therapeutics (HLS). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Medexus Pharmaceuticals vs.
Supreme Cannabis (TSE:FIRE) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings.
Supreme Cannabis received 54 more outperform votes than Medexus Pharmaceuticals when rated by MarketBeat users. Likewise, 85.33% of users gave Supreme Cannabis an outperform vote while only 71.43% of users gave Medexus Pharmaceuticals an outperform vote.
In the previous week, Medexus Pharmaceuticals' average media sentiment score of 0.51 beat Supreme Cannabis' score of 0.40 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media.
Medexus Pharmaceuticals has a consensus target price of C$5.49, suggesting a potential upside of 91.20%. Given Medexus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Medexus Pharmaceuticals is more favorable than Supreme Cannabis.
Medexus Pharmaceuticals has a net margin of 3.25% compared to Supreme Cannabis' net margin of 0.00%. Medexus Pharmaceuticals' return on equity of 11.07% beat Supreme Cannabis' return on equity.
Medexus Pharmaceuticals has higher revenue and earnings than Supreme Cannabis. Supreme Cannabis is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
8.3% of Medexus Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Medexus Pharmaceuticals beats Supreme Cannabis on 14 of the 16 factors compared between the two stocks.
Get Medexus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medexus Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:MDP) was last updated on 2/22/2025 by MarketBeat.com Staff
Free MDP Stock Alerts